Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study

Abd-Elsalam et al., Journal of Medical Virology, doi:10.1002/jmv.27122

Jun 2021

Source PDF All Studies Meta AnalysisMeta

RCT 164 hospitalized patients in Egypt showing lower mortality and shorter hospitalization, but without statistical significance. There were no serious adverse effects. Authors suggest the low dosage may have resulted in lower efficacy than other trials, and recommend increased dosage in future trials. Time from symptom onset is not specified. The trial was retrospectively registered and the recruitment start date in the trial registration (June 2020) differs from the paper (March 2020) osf.io. For other concerns see onlinelibrary.wiley.com.

This is the 25th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.

This is the 55th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).

1. onlinelibrary.wiley.com, onlinelibrary.wiley.com/doi/10.1002/jmv.28505.onlinelibrary.wiley.com/doi/10.1002/jmv.28505.

2. osf.io, osf.io/vjcnp/.osf.io/vjcnp/.

Important missing comments or errors? Let us know.

risk of death, 25.0% lower, RR 0.75, p = 0.70, treatment 3 of 82 (3.7%), control 4 of 82 (4.9%), NNT 82, odds ratio converted to relative risk, logistic regression, primary outcome.

risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 3 of 82 (3.7%), control 3 of 82 (3.7%).

hospitalization time, 19.6% lower, relative time 0.80, p = 0.09, treatment 82, control 82.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Abd-Elsalam et al., 2 Jun 2021, Randomized Controlled Trial, Egypt, peer-reviewed, 16 authors, study period March 2020 - October 2020, dosage 12mg days 1-3.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study

Sherief Abd‐elsalam, Rasha A Noor, Rehab Badawi, Mai Khalaf, Eslam S Esmail, Shaimaa Soliman, Mohamed S Abd El Ghafar, Mohamed Elbahnasawy, Ehab F Moustafa, Sahar M Hassany, Mohammed A Medhat, Haidi Karam‐allah Ramadan, Maii A S Eldeen, Mohamed Alboraie, Ahmed Cordie, Gamal Esmat

Journal of Medical Virology, doi:10.1002/jmv.27122

Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID-19 infected patients. This was a randomized open-label controlled study that included 164 patients with COVID-19. Patients were randomized into

References

Abd-Elsalam, Esmail, Khalaf, Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study, Am J Trop Med Hyg

Abd-Elsalam, Esmail, Khalaf, Tanta protocol for management of COVID-19: perspectives from a developing country

Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis

Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos, QJM

Behera, Patro, Singh, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, J Med Virol

Caccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, doubleblind, placebo-controlled, randomized clinical trial, EClinicalMedicine

Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res

Cappello, Marchetti, Parlanti, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep

Chaccour, Hammann, Ramón-García, Rabinovich, Ivermectin and COVID-19: keeping rigor in times of urgency, Am J Trop Med Hyg

Chachar, Khan, Asif, Tanveer, Khaqan et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci

Elgazzar, Eltaweel, Youssef, Hany, Hafez et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic

Faul, Erdfelder, Lang, Buchner, Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behav Res Methods

Galan, Santos, Asato, Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathog Glob Health, doi:10.1080/20477724.2021.1890887

Gallegos, WHO Declares Public Health Emergency for Novel Coronavirus, Medscape Medical News

Gandhi, Lynch, Del Rio, Mild or moderate COVID-19, N Engl J Med

Gorial, Mashhadani, Sayaly, Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)

Jans, Martin, Wagstaff, Inhibitors of nuclear transport, Curr Opin Cell Biol

Khan, Khan, Debnath, Ivermectin treatment may improve the prognosis of patients with COVID-19, Arch Bronconeumol, doi:10.1016/j.arbres.2020.08.007

Lundberg, Pinkham, Baer, Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication, Antiviral Res

Masoud, Elassal, Zaky, Management Protocol for COVID-19 Patients

Mccreary, Pogue, Coronavirus disease 2019 treatment: a review of early and emerging options, Open Forum Infect Dis

Medrxiv, None, doi:10.1101/2020.07.07.20145979

Mohamed, Mohamed, Mohamoud, SARS-CoV-2: the path of prevention and control

Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Biotechnol Biotechnol Equip

Podder, Chowdhury, Mohim, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study, IMC J Med Sci

Pott-Junior, Paoliello, Miguel, Use of ivermectin in the treatment of Covid-19: a pilot trial, Toxicol Rep

Prokop, Van Everdingen, Vellinga, CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19 definition and evaluation, Radiology

Rajter, Sherman, Vogel, Sacks, Rajter, Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest

Sharun, Dhama, Patel, Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Clin Microbiol Antimicrob, doi:10.1186/s12941-020-00368-w

Struyf, Deeks, Dinnes, Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease, Cochrane Database Syst Rev

Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin, Antiviral Res

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0